KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.10
+0.70 (0.28%)
AAPL  275.25
+5.82 (2.16%)
AMD  237.52
-6.46 (-2.65%)
BAC  53.63
+0.21 (0.39%)
GOOG  291.74
+1.15 (0.40%)
META  627.08
-4.68 (-0.74%)
MSFT  508.68
+2.68 (0.53%)
NVDA  193.16
-5.89 (-2.96%)
ORCL  236.15
-4.68 (-1.94%)
TSLA  439.62
-5.61 (-1.26%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.